Abstract-Cannabinoid compounds have been shown to produce antinociception and antihyperalgesia by acting upon cannabinoid receptors located in both the CNS and the periphery. A potential mechanism by which cannabinoids could inhibit nociception in the periphery is the activation of cannabinoid receptors located on one or more classes of primary nociceptive neurons. To address this hypothesis, we evaluated the neuronal distribution of cannabinoid receptor type 1 (CB1) in the trigeminal ganglion (TG) of the adult rat through combined in situ hybridization (ISH) and immunohistochemistry (IHC). CB1 receptor mRNA was localized mainly to medium and large diameter neurons of the maxillary and mandibular branches of the TG. Consistent with this distribution, in a de facto nociceptive sensory neuron population that exhibited vanilloid receptor type 1 immunoreactivity, colocalization with CB1 mRNA was also sparse «5%). Furthermore, very few neurons (approximately 5%) in the peptidergic (defined as calcitonin gene-related peptide-or substance P-immunoreactive) or the isolectin B4-binding sensory neuron populations contained CB1 mRNA. In contrast, and consistent with the neuron-size distribution for CB1, nearly 75% of CB1-positive neurons exhibited N52-immunoreactivity, a marker of myelinated axons. These results indicate that in the rat TG, CB1 receptors are expressed predominantly in neurons that are not thought to subserve nociceptive neurotransmission in the noninjured animal. Taken together with the absence of an above background in situ signal for CB2 mRNA in TG neurons, these findings suggest that the peripherally mediated antinociceptive effects of cannabinoids may involve either as yet unidentified receptors or interaction with afferent neuron populations that nonmally subserve non-nociceptive functions.
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While there is ample evidence for antinociceptive effects of cannabinoids in the CNS (Lichtman and Martin, 1991; Martin et aI., 1993 Martin et aI., , 1995 Smith et aI., 1994; Hohmann et aI., 1995; Lichtman et aI., 1996; Meng et aI., 1998) , there is a growing body of work indicating that cannabinoid antinociception also may be mediated at peripheral sites in the pain pathway. For example, peripherally administered anandamide, an endocannabinoid neurotransmitter, was shown to be antihyperalgesic when administered directly into the hind paw of carrageenaninflamed rats, and this effect was reversed by the selective CB1 antagonist SR141716A (Richardson et aI., 1998) . In addition to having direct effects on nociception, cannabinoids may have anti-inflammatory properties, as peripherally administered anandamide decreased carrageenanevoked plasma extravasation and decreased capsaicinevoked calcitonin gene-related peptide (CGRP) release from rat hind-paw skin (Richardson et aI., 1998 (Tominaga et aI., 1998) . VR1 is also activated by noxious heat or protons (Tominaga et aI., 1998) . Accordingly, the expression of VR1 by a neuron defines it as a nociceptor. It has been shown that activation of VR1 induces the release of neurotransmitters, including CGRP and SP, which cause vasodilation and increased vaso-permeability, respectively (Brain et aI., 1985; Gamse and Saria, 1985; Yonehara et aI., 1997; Holzer, 1988) . Thus, neurons that express one or both of these peptides playa major role in the development of neurogenic inflammation (via exocytosis from peripheral terminals) and hyperalgesia (via exocytosis from central terminals). Although the significance of IB4-binding to certain small to medium diameter neurons has not been fully appreciated, these neurons appear to be involved in both thermal and mechanical nociception (Vulchanova et aI., 2001 ) .
While it is likely that the peripheral antinociceptive effects of cannabinoids arise in part via activation of one or more cannabinoid-responsive receptors located on primary nociceptive neurons, the identity of these neurons, with respect to their neurochemical and functional phenotypes, is unknown. Therefore, an elucidation of the precise localization of cannabinoid receptors in nociceptive sensory neuron populations should provide a better understanding of cannabinoid analgesic mechanisms. In this regard, Hohmann and Herkenham (Hohmann and Herkenham, 1999b ) have demonstrated that CB1 mRNA is present in dorsal root ganglion (DRG) neurons and that this transcript colocalizes with a-CGRP and preprotakykinin A mRNA, although to only a modest degree (approximately 10%). Furthermore, CB1 receptors produced in the DRG undergo axonal transport to the periphery (Hohmann and Herkenham, 1999a) suggesting a functional role for CB1 receptors on peripheral nerve terminals. Neonatal capsaicin treatment, which abolishes capsaicin-sensitive sensory neurons (Jancso et aI., 1978) , reduced cannabinoid binding sites in the spinal dorsal horn by 16% (Hohmann and Herkenham, 1998) , implying that cannabinoid binding sites are localized, at least partially, to capsaicinsensitive nociceptors. In contrast, in cultured DRG neurons, CB 1-immunoreactivity overlaps almost completely with VR1-immunoreacitivty (Ahluwalia et aI., 2000), suggesting, at least in primary culture that CB1 and VR1 are found in the same neuronal populations. To date, CB1 expression in trigeminal ganglion (TG), however, has not been evaluated. Because of the physiological differences between the spinal and trigeminal systems (Tal and Devor, 1992; Bongenhielm et aI., 1998) , an evaluation of the neurochemical phenotype of CB1-expressing neurons in TG is an important research objective. Furthermore, an assessment of CB1 mRNA expression as it relates to the VR1-positive and IB4-binding nociceptive neuronal populations has not been executed through direct double-labeling studies in sensory ganglia. Thus, an analysis of CB1 mRNA expression in these nociceptive populations should shed light on potential mechanisms through which cannabinoids inhibit nociception in the periphery. Herein, we have characterized the neuronal distribution of CB1 in TG using combined in situ hybridization (ISH) and CGRP, SP, VR1 or N52 immunohistochemistry (IHC) or IB4-binding histochemistry (I BH) double-labeling.
EXPERIMENTAL PROCEDURES Animals and tissue preparation
Adult male Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) weighing approximately 175-225 g were used in this study. All procedures were approved by the Institutional Animal Care and Use Committee of The University of Texas Health Science Center at San Antonio and were conducted in accordance with policies for the ethical treatment of animals established by the Nationallnstitutes of Health. Every attempt was made to minimize the number of animals used and to reduce their suffering in the present study. Rats were killed by decapitation, and their TGs were promptly removed (approximately 120 s) and fresh frozen at -80°C in OCT compound (Sakura, Torrance, CA, USA). Tissue sections were cut (20 lim) on a Leica CM1800 cryostat (Bannockburn, IL, USA), thaw-mounted (10 min at room temperature) onto Superfrost Plus glass slides (VWR, West Chester, PA, USA) and stored at -80°C until use. For each experimental condition, one TG section was randomly chosen from each of three animals, and all ISH and IHC or IBH experiments were performed concurrently.
Single-labeling ISH
All chemicals were from Sigma (St. Louis, MO, USA) unless otherwise stated. A 5' CB1 fragment (11-554) and a 5' CB2 fragment were separately subcloned into Topo-TA pcr2.1 (Invitrogen, Carlsbad, CA, USA) from the full length rat CB1 cDNA (Acession number NM_012784), generously provided by Dr. Lisa Matsuda and full length rat cannabinoid receptor type 2 (CB2) cDNA (Acession number NM_020543), generously provided by Dr. Mary Abood, respectively. [35S]-labeled riboprobes were synthesized from the linearized CB1 and CB2 fragmentcontaining constructs using The Riboprobe Combination System SP6fT7 (Promega, Madison, WI, USA) incorporating 250 IiCi each of [35S]_CTP and [35S]_UTP (specific activity >800 Cilmmol; Amersham, Piscataway, NJ, USA). Riboprobes were purified by G-50 column chromatography (Ambion, Austin, TX, USA) and stored in hybridization buffer containing 50% formamide, 0.3 M NaCI, 10 mM Tris, 1 mM EDTA, 1 x Denhardt's solution, 10% dextran sulfate, 50 lig/ml yeast tRNA (Roche, Indianapolis, IN, USA) and 10 mM dithiothreitol at a concentration of 1X10B CPM/ml.
Tissue sections were prepared for hybridization by fixing in ice cold 3.7% formaldehyde for 1 hand permeabilizing with 0.5% Triton X-1 00 in 0.1 M Tris/0.05 M EDT A for 30 min. Sections were then acylated with acetic anhydride for 10 min, dehydrated, delipidated with chloroform, rehydrated and allowed to air dry. Dry sections were then hybridized in a humidified chamber with CB1 or CB2 riboprobes (40 IiL 1x 107 CPM/ml per TG section) in hybridization buffer for 16 h at 55°C. Following hybridization, sections were washed with 4 x SSC four times and treated with RNase I (20 lig/ml; Roche) for 30 min at 37°C. Washes were performed in decreasing concentrations of SSC, culminating in a final high stringency wash in 0.1 x SSC at 55°C for 30 min, then dehydrated and allowed to air dry. Finally, slides were emulsion dipped in NTB-3 (Kodak, Rochester, NY, USA) and developed 17 days later (for development of optimal signal). All sections were first subjected to ISH as described above; however, for the double-labeling method, sections were never allowed to air dry and were instead kept in 4x SSC at the end of prehybridization and 0.1 x SSC at the end of post-hybridization. Following hybridization, sections were blocked in PBS containing 10% normal goat serum (NGS; Gibco, Rockville, MD, USA) three times for 10 min. Next, primary antibody directed against CGRP, SP, VR1, N52 or peripherin or IB4 conjugated to Alexa-Fluor 488 (see Table 1 for commercial sources, dilutions, temperature and time of incubations), diluted in PBS containing 10% NGS and 1% fatty acid free bovine serum albumin, was applied. Sections were then washed three times in PBS and incubated for 1 h at room temperature in the appropriate secondary antibody (goat antirabbit or goat anti-guinea-pig diluted at 1 :300) conjugated to Alexa-Fluor 488 (Molecular Probes, Eugene, OR, USA). Slides were air-dried, emulsion dipped and developed after 17 days.
Image acquisition and analysis
All images were acquired using a Nikon E600 microscope (Melville, NY, USA) equipped with a Photometries SenSys digital CCD camera (Roper Scientific, Tucson, AZ, USA) connected to a computer equipped with Metamorph V4.1 image analysis software (Universal Image Corporation, Downingtown, PA, USA). For neuron size distribution measurements, 20x images were acquired and neurons with visible nuclei were measured for total area. Total area was then converted to an average diameter, and these values were pooled to create neuron size distribution frequency histograms. Similarly, for total neuron profiles of CB1-positive neurons, all neurons with visible nuclei over an entire TG section were assigned as either CB1-positive or CB1-negative based on the presence of above background silver grains associated with neurons (n=8 TG). For double labeling experiments, all neurons displaying fluorescent signal above background were counted as IHC-or IBH-positive. This was defined by scaling the image, using Metamorph's built-in scaling feature, to an average pixel value for negative neurons and establishing all neurons as positive that were above that threshold. Then, CB1 mRNA-positive cells were identified as in total neuron profile experiments above. The fluorescent IHC or IBH image and the dark field ISH image were then overlaid and analyzed for the presence of both signals to assess colocalization (n=3 TG/condition). Again, images were taken across an entire ganglion and data expressed as mean::!:S.E.M. colocalization percentage for one ganglion.
RESULTS
CB1 mRNA is localized to a sub-population of neurons in rat TG while CB2 mRNA is absent Hybridization of tissue sections with CB1 anti-sense riboprobes yielded specific labeling that was restricted to TG neurons (Fig. 1, upper panel) , while sense riboprobes exhibited no signal above background (data not shown). Interestingly, these CB1-positive neurons were found almost exclusively in those areas of the ganglia in which reside the somata that give rise to the mandibular and maxillary divisions of the trigeminal nerve but not the ophthalmic division (Fig. 1, upper  panel) . In contrast, immunoreactivity for peripherin, a marker of small diameter sensory neurons, was observed throughout the ganglion (Fig. 1, lower panel) . CB 1 mRNA was expressed mostly by neurons with diameters ranging from 40 to 80 J.1m (98.8%), with 61.3% of neurons having diameters greater than 60 J.1m (Fig. 2) . CB1 mRNA-positive neurons comprised 29.6%:t 5.6 of the total TG neuronal population (3034 positive neurons of 9913 total neurons counted over eight entire TG sections from eight different animals). On the other hand, CB2 mRNA was not found in rat TG while the control tissue, spleen, displayed high levels of CB2 mRNA confirming the activity of the riboprobe by autoradiography (Fig. 3) .
CB1 mRNA rarely colocalizes with the sensory neuron markers CGRP, SP, VR1 or IB4 Few CB1-positive neurons (4.9%:t2.2) contained VR1 immunoreactivity, and 3.5%:t 1.4 of VR1-positive neurons were CB1-positive. Furthermore, just 1.9%:t0.9 of CB1-positive neurons exhibited IB4 binding sites, while 2.0%:t1.5 of IB4-binding neurons expressed CB1 mRNA. Similarly, colocalization of CB1 mRNA with the neuropeptides CGRP or SP was relatively rare. Of CB1-positive neurons, only 7.5%:t2.0 contained CGRP immunoreactivity, and only 5.4%:t0.8 contained SP immunoreactivity. Likewise, CB1 expression in these peptidergic neuronal populations was small with 7.5%:t 1.2 of CGRP-positive neurons containing CB1 mRNA and 4.4%:t0.4 of SPpositive neurons containing CB1 mRNA. Representative samples of photomicrographs showing combined ISH/lHC or IBH are shown in Fig. 4 and the extent of this colocalization is quantitatively depicted in Fig. 5 .
CB1 mRNA colocalizes extensively with N52-immunoreactiivity, a marker of myelinated axons
The monoclonal antibody N52 selectively labels large diameter, myelinated neurons in native sensory ganglia. The majority of CB1 mRNA-positive neurons were N52-immunoreactive (75.1%:t6.9) while 39.9%:t7.3 of N52-immunoreactive neurons also contained CB1 mRNA (Fig. 6 ). This colocalization is depicted through a representative photomicrograph in Fig. 6 . 
DISCUSSION
In the present studies, the neuronal distribution and neurochemical colocalization of CB1 mRNA in TG was evaluated. The purpose of this investigation was to elucidate the neurochemical phenotype of certain cannabinoid-responsive trigeminal sensory neurons and, therefore, help to inform efforts to deduce the mechanisms that subserve peripheral cannabinoid analgesia. To this end, we found that approximately 30% of TG neurons contain CB 1 mRNA and that the majority of these give rise to fibers in the maxillary and mandibular divisions of the trigeminal nerve, while we found no evidence for the existence of CB2 transcripts in TG. Interestingly, the size distribution for CB1 mRNA-positive neurons indicates that these cells are likely members of the rapidly conducting A[3-fiber type involved with light touch and vibration sensation (Harper and Lawson, 1985; Lawson et aI., 1993) . Nevertheless, because the focus of peripheral actions of cannabinoids has been largely concentrated on nociception, we set out to explore the colocalization of CB1 mRNA with a number of markers that help define various nociceptor populations. To directly assess the distribution of CB1 mRNA in a de facto nociceptive neuronal population, colocalization of CB1 mRNA with VR1 immunoreactivity was explored. VR1-positive sensory neurons encode sensory information pertaining to noxious heat and pH and are thought to be, by definition, nociceptors. Only 5% of CB1 positive cells contained VR1 immunoreactivity, while even fewer VR1 immunopositive cells contained CB1 mRNA, indicating that only 1.5% of all TG neurons contain both CB1 mRNA and VR1 immunoreactivity. These results in native sensory ganglion tissue disagree with those from a study in cultured DRG neurons, wherein nearly all neurons containing CB1 immunoreactivity also contained VR1 immunoreactivity (Ahluwalia et aI., 2000) . This discrepancy may be due to a lack of antibody specificity and/or changes in neuronal phenotype that occur with neuronal culturing. In any case, such disparities point out important caveats to the comparison and interpretation of in vivo cellular localization data from primary cultures and native tissues. In addition, 1B4 binding sites, which are markers for a subset of unmyelinated nociceptors, rarely colocalized with CB1 mRNA. These data indicate that CB1 receptors are likely to be found mostly outside both the VR1 and IB4-binding nociceptor populations. Neuronal expression of the neuropeptides CGRP and SP roughly defines the peptidergic class of primary sensory neurons, many of which are thought to be nociceptive (Averill et aI., 1995) . Here again, very little colocalization was found between CB1 mRNA and either CGRP or SP immunoreactivity, in agreement with similar studies in DRG (Hohmann and Herkenham, 1999b ).
Because we saw very little overlap between the neuronal markers examined here and CB1 mRNA, and due to the neuronal size of the CB 1-positive population, we examined CB1 colocalization with the marker of myelinated sensory neurons, N52. More than 75% of CB1-positive neurons contained N52-immunoreactivity, indicating that CB1 is found nearly exclusively in myelinated, large diameter neurons. Furthermore, CB1 mRNA is in nearly half of the N52-positive population indicating that cannabinoid compounds acting through CB1 receptors may be major modulators of neurotransmission in this subclass of sen-
